ACAntony Clark

Antony Clark

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Antony Clark has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Corneal biometry changes with 0.01% atropine for myopia control: a randomised controlled trial and case of incidental keratoconus

    by Alvid Soh, Gareth Lingham, Elsie Chan, Antony Clark, David A. Mackey, Samantha Sze-Yee Lee

    Changes in corneal curvature have been reported with low-concentration atropine eyedrops for myopia treatment and have been suggested to play a role in the refractive changes observed during atropine therapy. A case of keratoconus was identified from the Western Australia atropine for the treatment of myopia (WA-ATOM) cohort. We tested the null hypothesis that 0.01% atropine eyedrops produce no change in corneal parameters or ectasia risk compared to placebo. Children with progressive myopia (6–16 years; n = 153) were randomly assigned to receive 0.01% atropine eyedrops or a placebo (2:1 ratio) for 2 years, followed by a 1-year washout. Scheimpflug imaging was performed at baseline, 24-months, and 36-months. Changes in corneal parameters were compared between the treatment and placebo groups using linear mixed models. One child allocated to the treatment group developed keratoconus during the treatment phase. At 24 and 36 months, the atropine group had significantly lower BAD-D values compared to placebo, with reductions of − 0.075 (95% CI − 0.126 to − 0.023, p = 0.027) and − 0.115 (95% CI − 0.168 to − 0.063, p = 0.005) from baseline, respectively ( p = 0.029 and 0.005). At 36 months, a significant steepening of K max of + 0.301D (95% CI 0.214 to 0.389, p = 0.039) was observed in the atropine group. All other corneal parameters and cylindrical power remained similar between the groups. The case of incidental keratoconus in the treatment group (1 out of 153 children) is compatible with population prevalence rates. No signal suggesting a treatment-related increase in corneal ectatic changes was identified within the limitations of this cohort, and these findings provide reassurance from a safety perspective, but clinicians should be aware of the rare possibility of keratoconus and refer patients with suspicious corneal findings.

  • Open Access

    Choroidal Changes During and After Discontinuing Long-Term 0.01% Atropine Treatment for Myopia Control

    by Samantha Sze-Yee Lee, Gareth Lingham, Antony Clark, Scott A. Read, David Alonso-Caneiro, David A. Mackey

    Purpose: Few studies have explored choroidal changes after cessation of myopia control. This study evaluated the choroidal thickness (ChT) and choroidal vascularity index (CVI) during and after discontinuing long-term low-concentration atropine eye drops use for myopia control. Methods: Children with progressive myopia (6–16 years; n = 153) were randomized to receive 0.01% atropine eye drops or a placebo (2:1 ratio) instilled daily over 2 years, followed by a 1-year washout (no eye drop use). Optical coherence tomography imaging of the choroid was conducted at the baseline, 2-year (end of treatment phase), and 3-year (end of washout phase) visits. The main outcome measure was the subfoveal ChT. Secondary measures include the CVI. Results: During the treatment phase, the subfoveal choroids in both treatment and control groups thickened by 12–14 µm (group difference P = 0.56). During the washout phase, the subfoveal choroids in the placebo group continued to thicken by 6.6 µm (95% confidence interval [CI] = 1.7 to 11.6), but those in the atropine group did not change (estimate = -0.04 µm; 95% CI = –3.2 to 3.1). Participants with good axial eye growth control had greater choroidal thickening than the fast-progressors during the treatment phase regardless of the treatment group (P < 0.001), but choroidal thickening in the atropine group's fast-progressors was not sustained after stopping eye drops. CVI decreased in both groups during the treatment phase, but increased in the placebo group after treatment cessation. Conclusions: On average, compared to placebo, 0.01% atropine eye drop treatment did not cause a differential rate of change in ChT during treatment, but abrupt cessation of long-term 0.01% atropine eye drops may disrupt normal choroidal thickening in children.


  • Open Access

    Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia – Atropine for the Treatment of Myopia (WA‐ATOM) study

    by Samantha Sze‐Yee Lee, Vinay Kumar Nilagiri, Gareth Lingham, Magdalena Blaszkowska, Paul G. Sanfilippo, Maria Franchina, Antony Clark, David A. Mackey

    Background: A rebound in myopia progression following cessation of atropine eyedrops has been reported, yet there is limited data on the effects of stopping 0.01% atropine compared to placebo control. This study tested the hypothesis that there is minimal rebound myopia progression after cessation of 0.01% atropine eyedrops, compared to a placebo.Methods: Children with myopia (n = 153) were randomised to receive 0.01% atropine eyedrops or a placebo (2:1 ratio) daily at bedtime during the 2‐year treatment phase of the study. In the third year (wash‐out phase), all participants ceased eyedrop instillation. Participants underwent an eye examination every 6 months, including measurements of spherical equivalent (SphE) after cycloplegia and axial length (AL). Changes in the SphE and AL during the wash‐out phase and throughout the 3 years of the study (treatment + wash‐out phase) were compared between the treatment and control groups.Results: During the 1‐year wash‐out phase, SphE and AL progressed by −0.41D (95% CI = −0.33 to −0.22) and +0.20 mm (95% CI = −0.46 to −0.36) in the treatment group compared to −0.28D (95% CI = 0.11 to 0.16) and +0.13 mm (95% CI = 0.18 to 0.21) in the control group. Progression in the treatment group was significantly faster than in the control group (p = 0.016 for SphE and <0.001 for AL). Over the 3‐year study period, the cumulative myopia progression was similar between the atropine and the control groups.Conclusions: These findings showed evidence of rapid myopia progression following cessation of 0.01% atropine. Further investigations are warranted to ascertain the long‐term effects of atropine eyedrops.


  • Top Cited Papers
    Open Access

    Low‐concentration atropine eyedrops for myopia control in a multi‐racial cohort of Australian children: A randomised clinical trial

    by Samantha Sze‐Yee Lee, Gareth Lingham, Magdalena Blaszkowska, Paul G. Sanfilippo, Adrian Koay, Maria Franchina, Audrey Chia, James Loughman, Daniel Ian Flitcroft, Christopher J. Hammond, et al.

    Background: To test the hypothesis that 0.01% atropine eyedrops are a safe and effective myopia‐control approach in Australian children.Methods: Children (6–16 years; 49% Europeans, 18% East Asian, 22% South Asian, and 12% other/mixed ancestry) with documented myopia progression were enrolled into this single‐centre randomised, parallel, double‐masked, placebo‐controlled trial and randomised to receive 0.01% atropine (n = 104) or placebo (n = 49) eyedrops (2:1 ratio) instilled nightly over 24 months (mean index age = 12.2 ± 2.5 and 11.2 ± 2.8 years, respectively). Outcome measures were the changes in spherical equivalent (SE) and axial length (AL) from baseline.Results: At 12 months, the mean SE and AL change from baseline were −0.31D (95% confidence interval [CI] = −0.39 to −0.22) and 0.16 mm (95%CI = 0.13–0.20) in the atropine group and −0.53D (95%CI = −0.66 to −0.40) and 0.25 mm (95%CI = 0.20–0.30) in the placebo group (group difference p ≤ 0.01). At 24 months, the mean SE and AL change from baseline was −0.64D (95%CI = −0.73 to −0.56) and 0.34 mm (95%CI = 0.30–0.37) in the atropine group, and −0.78D (95%CI = −0.91 to −0.65) and 0.38 mm (95%CI = 0.33–0.43) in the placebo group. Group difference at 24 months was not statistically significant (p = 0.10). At 24 months, the atropine group had reduced accommodative amplitude and pupillary light response compared to the placebo group.Conclusions: In Australian children, 0.01% atropine eyedrops were safe, well‐tolerated, and had a modest myopia‐control effect, although there was an apparent decrease in efficacy between 18 and 24 months, which is likely driven by a higher dropout rate in the placebo group.


  • The epidemiology of eye injuries in Western Australia: a retrospective 10-year study

    by Magda K Blaszkowska, Stephen E Bartnik, Julie M Crewe, Antony Clark, David A Mackey

    Eye injuries constitute a significant cause of preventable lifelong visual impairment or blindness. It is important to identify the context in which these injuries occur to develop intervention pro...


  • Open Access

    Distribution and Classification of Peripapillary Retinal Nerve Fiber Layer Thickness in Healthy Young Adults

    by Gareth Lingham, Samantha Sze-Yee Lee, Jason Charng, Antony Clark, Fred K. Chen, Seyhan Yazar, David A. Mackey

    Purpose: To report the distribution of peripapillary retinal nerve fiber layer (RNFL) thickness in healthy young adults, investigate factors associated with RNFL thickness, and report the percentage of outside normal limits (ONL) and borderline (BL) RNFL thickness classifications based on the optical coherence tomography (OCT) manufacturer reference database. Methods: Participants of the Raine Study Generation 2 cohort (aged 18–22 years) underwent spectral domain OCT imaging with an RNFL circle scan. Eyes with inadequate scans or optic nerve pathology were excluded. Linear mixed models were used to analyze associations. Results: Data were available for 1288 participants (mean age, 20.0 years). Mean RNFL thicknesses in right and left eyes, respectively, were global = 100.5 µm, 100.3 µm (P = 0.03); temporal = 73.1 µm, 68.9 µm (P < 0.001); superotemporal = 140.6 µm, 136.3 µm (P < 0.001); superonasal = 104.9 µm, 115.1 µm (P < 0.001); nasal = 79.7 µm, 79.1 µm (P = 0.09); inferonasal = 109.8 µm, 111.5 µm (P < 0.001); and inferotemporal = 143.2 µm, 143.6 µm (P = 0.51). Longer axial length was associated with thinner RNFL globally, nasally, inferotemporally, superotemporally, superonasally, and inferonasally, as well as thicker RNFL temporally. The prevalence of ONL and BL classifications was generally higher than the expected rates of 1% and 4%, respectively, in temporal sectors and lower than expected in nasal sectors. The prevalence of global BL classifications was lower than expected (right eye, 2.3%; left eye, 2.6%). Conclusions: Measured RNFL thickness differs with axial length and between right and left eyes. More reference data are needed to better define the normal limits of RNFL variation in different populations. Translational Relevance: This study provides an improved understanding of normal variation in RNFL thickness in young adults.


  • Non‐accidental and accidental eye injuries in children in Western Australia

    by Antony Clark, Swati Sinkar, Kate Barnes, Geoffrey C. Lam, Alice H. Johnson, David A. Mackey


  • Western Australia Atropine for the Treatment of Myopia (WA‐ATOM) study: Rationale, methodology and participant baseline characteristics

    by Samantha S.Y. Lee, David A. Mackey, Gareth Lingham, Julie M. Crewe, Michael D. Richards, Fred K. Chen, Jason Charng, Fletcher Ng, Ian Flitcroft, James J. Loughman, et al.

    Importance: Atropine eyedrops are a promising treatment for slowing myopia progression in East Asian children. However, its effects on children in Australia, including those of non‐Asian background, have not been well‐studied.Background: The Western Australia Atropine for the Treatment of Myopia (WA‐ATOM) study aims to determine the efficacy and long‐term effects of low‐dose atropine eyedrops in myopia control. This paper describes the study rationale, methodology and participant baseline characteristics.Design: Single‐centre, double‐masked, randomized controlled trial.Participants: Children (6‐16 years) with spherical equivalent ≤−1.50 D in each eye, astigmatism ≤1.50 D and myopia progression by ≥0.50 D/year.Methods: Enrolled children were randomly assigned 2:1 to receive 0.01% atropine or placebo eyedrops. Participants are examined every 6 months during first 3 years of the study (2‐year treatment phase followed by a 1‐year washout phase), and then at a 5‐year follow‐up (2 years after the end of the washout phase).Main Outcome Measures: Annual progression rate of myopia and axial length, tolerability to eyedrops and incidence and severity of unwanted effects.Results: Out of 311 children who were referred, 242 were suitable for study participation, and 153 were subsequently enrolled. The baseline characteristics of enrolled participants are presented.Conclusions and Relevance: Outcomes of the WA‐ATOM study will inform on the efficacy, tolerability, safety and long‐term effects of low‐dose atropine eyedrops in myopia control in Australian children. The impact of ocular sun exposure, iris colour and parental myopia on the efficacy of low‐dose atropine will also be assessed.


  • Electron Microscopic Evidence of Photoreceptor Outer-segments in the Trabecular Meshwork in a Case of Schwartz-Matsuo Syndrome

    by Antony Clark, Alaa Alkhotani, Yeni H. Yucel, Carly Sylvester, Peter J. Kertes, Catherine M. Birt

    Purpose: To describe a case of photoreceptor outer segment glaucoma (Schwartz-Matsuo syndrome) with electron microscopic evidence of photoreceptor outer segments in the trabecular meshwork (TM). Design: This is a clinicopathologic case report. Participant: A 48-year-old Filipino man. Methods: Specimens of aqueous humor and TM in a clinical case of Schwartz-Matsuo syndrome were examined by electron microscopy. Main Outcome Measures: Electron photomicroscopy. Results: Electron microscopy showed evidence of retinal photoreceptor outer-segments in both an aqueous humor and a TM specimen. Conclusion: Schwartz-Matsuo syndrome is associated with the presence of photoreceptor outer segments in the TM.